A DIRECT LHRH-AGONIST ACTION ON CANCER-CELLS IS UNLIKELY TO BE THE CAUSE OF RESPONSE TO LHRH-AGONIST TREATMENT

  • 1 January 1989
    • journal article
    • research article
    • Vol. 9  (1) , 77-80
Abstract
LHRH-Agonist therapy has been shown to have some effect in cancer treatment. Chronic administration of LHRH-agonists may lead to a decreased gonadal steroidogenesis. A direct anti-tumor action of LHRH-agonists has also been reported. We observed only a small direct inhibitory effect on the LHRH-agonist Buserelin at high concentrations on the proliferation of three human ovarian cancer cell lines, and on estrogen-stimulated proliferation of human breast cancer cells in vitro. Proliferation of rat prostate cancer cells was not inhibited by Buserelin. It is unlikely that a direct anti-tumor effect is the major mechanism of action of LHRH-agonists in cancer treatment.